韩国生物医药产业创新发展政策研究  

Policy Research on Innovation and Development of South Korea􀆳s Biopharmaceutical Industry

作　　者：莫富传 胡海鹏 袁永 MO Fu-chuan;HU Hai-peng;YUAN Yong(Guangdong Science and Technology Innovation Monitoring and Research Center,Guangzhou 510033,China)

机构地区：[1]广东省科技创新监测研究中心,广东广州510033

出　　处：《科技创新发展战略研究》2021年第3期64-70,共7页Strategy for Innovation and Development of Science and Technology

基　　金：广东省软科学研究项目“广东推进粤港澳大湾区国际科技创新中心建设相关配套政策研究”(2018B070715002);广东省科技计划项目“应对重大疾病防控应急科研攻关的生物医药产业创新发展战略规划研究”(2020B1111330004)。

摘　　要：韩国生物医药产业在全球占据重要地位,拥有众多知名研发型制药企业和一批高影响力的医院,生命科学与医学类高校享有国际声誉。通过总结韩国生物医药产业在中长期发展规划、临床研究监管、医疗保险药品目录调整、韩医科研和产业发展、国际合作与交流以及创新型药学人才等方面的政策措施,提出我国进一步加强生物医药政策法规建设、体制机制创新、落实风险管控和伦理审查、积极促进中医药创新发展以及培育生物医药创新型人才等建议,以促进我国生物医药产业创新发展。Korea􀆳s biopharmaceutical industry occupies an important position in the world with many well-known research and development pharmaceutical companies,a number of high-impact hospitals and some life sciences and medical universities which enjoy an international reputation.This paper summarizes the policy measures of Korea􀆳s biopharmaceutical industry in the areas of medium and long-term development planning,clinical research supervision,adjustment of medical insurance drug catalogue,development of Korean medical research and industry,international cooperation and exchange and innovative pharmaceutical talents,and suggests that China should further strengthen the construction of biopharmaceutical policies and regulations,innovation of system and mechanism,implementation of risk control and ethical review,actively promoting the innovation and development of Chinese medicine and cultivating innovative talents in biopharmaceuticals,so as to promote the innovation and development of China􀆳s biopharmaceutical industry.

关 键 词：生物医药 产业创新 韩医 临床试验监管 

分 类 号：F426.72[经济管理—产业经济]